BioMarin Pharmaceutical Inc. BMRN

Company Overview

BioMarin Pharmaceutical Inc. is a U.S.-based biotechnology company focused on developing and commercializing therapies for serious and life-threatening rare genetic diseases. The company operates primarily within the biotechnology and orphan-drug sectors, with a concentration on enzyme replacement therapies, gene therapies, and precision medicines targeting inherited metabolic and genetic disorders. BioMarin’s commercial portfolio includes treatments for achondroplasia, phenylketonuria (PKU), hemophilia A, mucopolysaccharidosis, and other ultra-rare conditions. Revenue is primarily generated through global product sales, particularly from VOXZOGO, VIMIZIM, NAGLAZYME, PALYNZIQ, and ROCTAVIAN.

BioMarin has historically positioned itself as a specialist in rare disease therapeutics, benefiting from regulatory exclusivity periods, high barriers to entry, and deep expertise in orphan-drug development. The company was founded in 1997 and grew through a combination of internal research, licensing agreements, and targeted acquisitions. Over time, BioMarin evolved from an early-stage enzyme therapy developer into a globally commercialized biotechnology company with approved therapies across multiple rare disease indications. Its strategy has emphasized long development cycles in underserved patient populations where competition is relatively limited and reimbursement support is often stronger due to unmet medical need.